Neuralink N2 — Expanded Clinical Programme
Neuralink

Neuralink N2 — Expanded Clinical Programme

Invest in the future of human-computer symbiosis

30%+

Expected Yield

$10,000

Min. Investment

$19.4M

Raised

0

Investors

210d

Days Left

$19.4M raised24.3%
of $80.0M210d left

Min. investment: $10,000 · Goal: $80.0M

Scroll to explore

The Opportunity

Why This Project

Neuralink's N2 device programme expands the PRIME study to 50 paralysis patients across 12 sites globally, while advancing the R&D roadmap toward a second-generation implant with 10× electrode density and wireless charging. This raise supports clinical operations, device manufacturing scale-up, and regulatory pathway for FDA Breakthrough Device approval.

  • First BCI to achieve sustained telepathic cursor control in humans
  • FDA Breakthrough Device designation secured
  • N2 device targets 10× electrode density vs N1
  • 50-patient PRIME expansion across 12 global sites
  • Licensing pipeline value estimated at $8B by independent analysts

Project Metrics

Projected Yield30%+
Yield TypeOn Exit
Raise Target$80M
Minimum Entry$10,000
Active Investors143
Risk ProfileVery High Risk

Investment Tiers

Choose Your Entry Point

Returns

Calculate Your Investment

Investment Calculator

Estimate your projected returns.

$
$10,000$74,999

Projected Return

$3,000 – $5,000

Total Value

$13,000 – $15,000

Based on 30%–50% projected yield for the Explorer tier. Projections are estimates, not guarantees.

Timeline

Project Milestones

Aug 2025

PRIME study first patient implanted

Jun 2026

12-month PRIME interim data published

Sep 2026

N2 device design freeze

Jan 2027

50-patient expansion fully enrolled

Apr 2028

FDA PMA submission

Limited Availability

Secure Your Position

Spots across all tiers are limited. Once filled, this offering closes regardless of the deadline.

This is not an offer to sell or a solicitation of an offer to buy securities. Investment in private market opportunities involves significant risk, including the potential loss of your entire investment. All projected yields are estimates based on current models and are not guaranteed. Past performance does not indicate future results. Please review all project documents carefully before investing.